In mice, the CD3 signaling complex was recently successfully manipulated by a mono Fab anti-CD3ε therapy is able to boost the activation of antigen-specific CD8+ T cells and results in decreased tumor burden [4]. The gene discussed is CD8A; the disease is neoplasm.